Showing results (221-230 of 365) with videos related to
Sort By:
Pageof 37
Investigational New Drugs|September 18, 1998
Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapyM J Edelman, D R Gandara, E A Perez, et al.Forensic Science International|February 22, 2002
16 X-chromosome STR loci frequency data from a German populationJ Edelman, S Hering, M Michael, et al.Science Robotics|October 29, 2019
Noninvasive neuroimaging enhances continuous neural tracking for robotic device controlB J Edelman, J Meng, D Suma, et al.Clinical Lung Cancer|October 16, 2012
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung CancerDavid R Spigel, Martin J Edelman, Tony Mok, et al.Cancer|December 24, 2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara, Frederick J Meyers, Lisa Y Law, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancerCharles M Rudin, Mark Kozloff, Philip C Hoffman, et al.Cancer|April 10, 2004
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urotheliumRobert Dreicer, Judith Manola, Bruce J Roth, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara, Mary W Redman, Karen Kelly, et al.Imaging Neuroscience (Cambridge, Mass.)|October 28, 2024
NOise Reduction with DIstribution Corrected (NORDIC) principal component analysis improves brain activity detection across rodent and human functional MRI contextsRussell W Chan, Giles Hamilton-Fletcher, Bradley J Edelman, et al.Advances in Therapy|August 15, 2019
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid TumorsSanjeevani Arora, Rodion Velichinskii, Randy W Lesh, et al.Pageof 37